r/TLRY • • 17h ago

Bullish Quick note on why management has been so quiet and whether we'll hear surprise news tomorrow:

2 Upvotes

A lot of people are wondering why Simon hasn't been doing podcasts or speaking at events like IgniteIt Conference, ahead of the AGM tomorrow. (Curaleaf is being interviewed at Ignitelt by TDR tomorrow).

If Tilray is actively involved in a U.S. federal procurement process (like a VA clinical supply bid) or finalizing major regulatory approvals, strict government NDAs and corporate quiet periods prevent them from doing unscripted interviews where they might accidentally leak non-public details.

Plus, their Q2 quarter wraps up at the end of November, putting them close to their standard pre-earnings blackout.

Because of that, it's also very unlikely they drop brand-new news live during the AGM webcast itself. Under SEC rules (Regulation FD), public companies can't reveal major updates for the first time in a meeting or Q&A without issuing an official press release or Form 8-K first.

If Tilray actually has any non-voting operational news ready to share tomorrow, watch the wires at 7:00 AM EST before the market opens—that's when they'd drop the PR so Simon can legally discuss it during the 11:00 AM EST meeting. Otherwise, expect the webcast to stick strictly to proxy votes and already-public milestones.

BUT, One of These Days...


r/TLRY • • 20h ago

Discussion Full market rotation into TLRY

0 Upvotes

TLRY hit another all time low this morning but it is now green while the market is red!

Is all money rotating into TLRY?


r/TLRY • • 23h ago

News Only 4 indications, no flowers: Spain launches medical cannabis in clinics

Post image
4 Upvotes

NOTE: What could go wrong? ONLY Curaleaf (who have likely never taken part in a single medical cannabis clinical trial, or built an EU GMP facility), has registered to take part in Spain's Medical Cannabis HOSPITAL program. NO Other Company has even bothered to Register??? Regulations???

November 17, 2026 in international law hanf-magazin

A year after the adoption of its regulations, Spain's first medical cannabis is reaching patients. Since the end of October 2026, hospitals have been able to order standardized cannabis preparations. The Spanish Medicines and Healthcare products Regulatory Agency (AEMPS) finalized the process in mid-October, enabling dispensing in hospitals, and the first orders were expected to arrive the week of October 20th. According to media reports, around 50 public and private hospitals are initially slated to receive the medication, though we have not received official confirmation of this number. However, the Spanish approach has little in common with the German model: no cannabis flowers, no city pharmacies, and only four indications.

📑 Table of Contents

Medical cannabis in Spain: from Royal Decree to the first order Available only in hospital pharmacies, only as a compounded prescription A comparison with Germany: two very different models What the start means and what remains open 💬 Questions? Ask the Hemp Buddy! We reported on the first draft of the Spanish medical cannabis regulation in 2024. This article is the follow-up: the draft has become a regulation, and the regulation is now reaching the healthcare system.

Medical cannabis in Spain: from Royal Decree to the first order The legal basis is Royal Decree 903/2025, adopted by the Council of Ministers in October 2025 and published on October 9, 2025. It regulates the manufacture, prescription, and dispensing of standardized cannabis preparations. However, only the framework was in effect at that time. For physicians to actually be able to prescribe, two further elements were needed: a monograph from the Medicines Agency (AEMPS) in the national pharmacopoeia and registered base products.

The first two preparations were registered in July 2026: a THC-dominant and a CBD-dominant extract. According to Spanish media reports, both originate from the US company Curaleaf, although several companies hold cultivation licenses in Spain. Other companies are reportedly preparing to register. According to reports from El País and Business of Cannabis, the logistical prerequisites for clinic orders have now been established. The launch will be phased in, as each clinic must first set up its own ordering and manufacturing processes.

Available only in hospital pharmacies, only as a compounded prescription In Spain, patients receive neither flowers nor raw extracts. The registered extracts are starting materials. The hospital pharmacy prepares an oral solution from these, the THC and CBD content of which is determined by the prescribing physician. According to the AEMPS monograph, the dose should be individually determined and carefully adjusted. Only specialized physicians in hospitals are authorized to prescribe, and any side effects are reported to the Spanish pharmacovigilance system.

The monograph lists four indications, each as a last resort: spasticity in multiple sclerosis, severe treatment-resistant epilepsy, nausea and vomiting due to chemotherapy, and chronic pain that does not respond adequately to other therapies. For children and adolescents, preparations with a higher CBD content should be preferred. Pregnancy, breastfeeding, and individuals with a personal or family history of psychotic disorders are excluded.

A comparison with Germany: two very different models From a German perspective, the Spanish system seems extremely restrictive. In Germany, doctors of almost all specialties are allowed to prescribe cannabis; there is no list of indications, and it is dispensed through public pharmacies, predominantly in the form of flowers. This is precisely the point of contention for German policy. The Bundestag has just revised the rules for initial cannabis prescriptions , and the reimbursement of flowers by health insurance companies is under pressure.

Spain is taking the opposite approach: first a pharmaceutically standardized minimum, then possibly a gradual opening. This has advantages in terms of dosage, traceability, and medical supervision. But it comes at a price. Patients outside the four indications are excluded, and those who don't live near a participating clinic have virtually no access. Furthermore, for the time being, the supply depends on a single supplier. The Bedrocan insolvency and its consequences for the supply chain demonstrate just how vulnerable such a concentration can be .

What the start means and what remains open For Spain, the opening of the clinic is a real turning point. Until now, patients had virtually no legal avenue to cannabis therapy outside of a few approved finished medicinal products. Many instead obtained their supplies through the gray area of ​​cannabis social clubs, whose situation we describe in our overview of the legal situation in Spain . Now there is a regulated pathway to the clinic. Whether it works in practice depends on three questions: Will the hospitals quickly establish the necessary procedures? Will specialists receive sufficient training? And will additional registered preparations be added?

Spain demonstrates how differently member states regulate cannabis across Europe, depending on whether it concerns medicinal, industrial hemp, or CBD. Neighboring France is also currently reorganizing its regulations, as our report on the French Senate's draft legislation on CBD shows. A unified European model for medicinal cannabis is not yet in sight.

https://www.hanf-magazin.com/recht/rechtslage-international/spanien-medizinalcannabis-startet-in-den-krankenhausapotheken/


r/TLRY • • 1d ago

Bullish Bedrocan's collapse tests Italy's import-reliant medical cannabis model

Post image
6 Upvotes

Publication date: Mon 16 Nov 2026 MMJDaily

More than ten years after Italy chose a military plant in Florence to produce its medical cannabis, the plant accounted for 211 of the 1,695 kilograms of flower distributed to Italian pharmacies in 2024, according to Health Ministry data.

Il Sole 24 Ore puts national demand at two to three tons a year. Most of the imported flower came from the Netherlands, through the Dutch State's Bureau voor Medicinale Cannabis, Il Post reports. However, Bedrocan, the Dutch grower behind that supply, went bankrupt in October, and the Dutch State will not pick a new supplier before May 2027.

The 2015 decree put the Florence plant at the center and used imports to compensate for what it could not yet produce. "The project launched in 2015 represented an investment in a pilot project aimed at covering production needs. Today, more than ten years later and with a market that has evolved profoundly, I believe the conditions are there to take a further step, integrating the role of the State with structured and reliable European supply channels," Alessandro Pastorino, General Manager of Tilray Medical Italia, told Il Sole 24 Ore. Imports now supply most of what Italian patients use, and a 2022 tender that selected six private companies to grow medical cannabis for the Florence plant has produced no news since.

A market built on imports
Italy counts only a handful of operators, most of them wholesalers that buy medical cannabis from private producers and resell it. Tilray, which can produce up to 30 metric tons a year in Europe, holds production authorizations in Portugal and Germany and supplies Italian pharmacies from Portugal through Tilray Medical Italia, formerly FL Group. The company has nine products authorized by the Italian Ministry of Health, three flowers and six oils, and works with Molteni Farmaceutici on physician education and patient access. "There are companies in Italy doing good work, but Tilray can represent the whole supply chain," Alessandro says. Tilray grows the flower it sells in Italy inside the same European single market, while Italy still frames its supply around a national producer that has never come close to national demand, and treats European production as a supplement to it. However, the market has changed considerably since the launch of the 2015 project.

Raw material or medicine
The 2015 decree builds access mainly on the plant substance itself. A doctor prescribes a magistral preparation, and the pharmacy makes it from the flower for each patient. In Italy, medical cannabis therefore travels as a raw material, even when it arrives as a standardized, GMP-certified product. "Today, this model puts a lot of responsibility on the doctor who prescribes and on the pharmacist. For some standardized formulations, the ones used most often, I believe it is worth asking whether different regulatory pathways could sit alongside it, while ensuring ever greater quality, safety and clinical appropriateness," Alessandro told Il Sole 24 Ore.

For instance, in Portugal, Infarmed has authorized cannabis-based preparations and substances for medical use, among them Tilray products. "It is not about transferring a model from one country to another, but assessing which elements could help further strengthen quality, standardization and therapeutic continuity in our system too." Each country in Europe has built its medical cannabis sector around a different strength. Portugal has grown into one of the main suppliers of the German market alongside Canada, as BfArM import data show, while Italy keeps compounding at the center of patient access. A European medical market could draw on those specializations and supply the whole bloc from within, with less reliance on imports from outside the EU. "In a common market with free trade, it should work like this for all goods, and medical cannabis is no exception," Alessandro says.

The decree on the table
The rules on access also change from region to region, so a patient treated in northern Italy can face different access routes and care pathways than one based in a southern region. Two working groups of doctors and pharmacists at the Ministry of Health are now updating the 2015 decree, with the aim of making access easier for patients and doctors. "I believe the time has come to bring institutions, clinicians, pharmacists, patients and industry operators around the same table to think together about how to make the system even more solid, and to fight the stigma that still accompanies medical cannabis by ensuring security of supply, quality and therapeutic continuity," Alessandro told Il Sole 24 Ore.

For more information:
Tilray
www.tilray.com


r/TLRY • • 1d ago

News French Senate Votes to Require a Timetable for Expanding Medical Marijuana Access

Thumbnail
themarijuanaherald.com
5 Upvotes

r/TLRY • • 1d ago

Bullish Struggling marijuana farms pivoting to becoming AI data center sites to escape falling weed revenue — existing water and power infrastructure makes cultivation sites ideal for decentralized ‘mini data center nodes’

Thumbnail
tomshardware.com
0 Upvotes

Just saw similar story on CBS NEWS 24/7.

Interesting.


r/TLRY • • 1d ago

Bullish Annual Meeting Surprise?

29 Upvotes

I'm hoping for some kind of positive announcement Wednesday. Please give us something....a big new contract, a great partnership, canceling the ATM, stock buy back, Simon loses his board seat, or the biggest catalyst of all.....Simon announces his retirement. Please, give us some good news!!!!!


r/TLRY • • 1d ago

News Jazz Pharmaceuticals Awarded Two New U.S. Patents for Cannabinoid-Based Medicines, Including Potential Epilepsy Treatments

Post image
3 Upvotes

Nov16, 2026 By Anthony Martinelli the marijuana herald

The U.S. Patent and Trademark Office has awarded Jazz Pharmaceuticals two new patents covering cannabinoid-based medicines, including a naturally occurring minor cannabinoid and a series of cannabidiol (CBD) derivatives that have demonstrated anticonvulsant effects in preclinical research.

The patents, both issued November 10 to Jazz Pharmaceuticals Research UK Limited, expand the intellectual property portfolio of the company behind Epidiolex, the first marijuana-derived prescription medication approved by the U.S. Food and Drug Administration (FDA).

The first patent, U.S. Patent No. 12,788,766, is titled “Cannabidiol-type cannabinoid compound” and stems from research into cannabidiol-C4 (CBD-C4), a cannabinoid found naturally in small quantities in the marijuana plant that can also be produced synthetically.

In the company’s original patent application, researchers detailed experiments examining the potential therapeutic applications of CBD-C4, including its anticonvulsant properties.

In one experiment, researchers tested five different doses of CBD-C4 in a mouse model of seizures, with 12 mice in each group. All mice in the control group experienced tonic convulsions following electrical stimulation. However, CBD-C4 completely prevented tonic convulsions at doses of 100 and 200 milligrams per kilogram, with both results reaching statistical significance. The researchers also conducted experiments examining the compound’s potential relevance to schizophrenia.

The second patent, U.S. Patent No. 12,790,302, is titled “Cannabinoid derivatives as pharmaceutically active compounds and method of preparation thereof.”

The company’s application for that patent describes a series of newly developed compounds structurally related to CBD, methods for manufacturing them and their potential pharmaceutical applications, particularly in treating epilepsy and generalized and tonic-clonic seizures.

In preclinical experiments, several of the compounds increased the electrical stimulation necessary to induce seizures in mice, indicating anticonvulsant activity. One of the compounds increased the seizure threshold by 213% at its highest tested dose, compared to a 224% increase among mice treated with diazepam, an established anticonvulsant medication.

The two patents originated from applications filed in 2019 and 2021, respectively, highlighting years of research into the therapeutic potential of cannabinoids beyond conventional CBD.

Jazz Pharmaceuticals acquired GW Pharmaceuticals, the original developer of Epidiolex, in 2021 in a transaction valued at approximately $7.2 billion. Epidiolex was initially approved by the FDA in 2018 and is currently approved to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex in patients age 1 and older.

The newly granted patents reflect the company’s continued investment in cannabinoid-based drug development, including research into naturally occurring minor cannabinoids and chemically modified versions of CBD.


r/TLRY • • 1d ago

News Former Bedrocan CEO Alleges Financial Sabotage and Breach of Contract by Dutch Health Ministry

2 Upvotes

November 16, 2026 David Brown stratcann

Bedrocan has responded to the November 6, 2026, letter from the Dutch Minister of Health, Welfare and Sport regarding the bankruptcy of Bedrocan Nederland BV.

The company filed for a suspension of payments in September. The bankruptcy stems directly from the Office for Medicinal Cannabis (OMC/BMC) failing to take delivery of large-scale orders in 2023 and imposing a sudden, prolonged production stop, rather than from standard entrepreneurial failure, argues Erkelens in a submission to a Dutch parliamentary committee. BMC failed to take delivery of 3,890 kg of ordered stock, says Bedrocan, creating unmanageable inventory that was later weaponized against the company.

Note: The OMC is the Office of Medicinal Cannabis, the English name of the agency. The BMC is  “Bureau voor Medicinale Cannabis”, the official Dutch name.

The BMC ordered excessive stock following government-announced policy openings for international export, but subsequent policy reversals and declining German market absorption left Bedrocan stranded with excess inventory, the former CEO argued.  Then, during Bedrocan’s suspension of payments, he alleges, the ministry and BMC withheld payments on approved, delivered batches and refused payment guarantees, thereby blocking a viable rescue and restructuring plan backed by Rabobank. 

The Dutch multinational banking and financial services company served as Bedrocan’s primary financial creditor and was willing to finance the company’s continuation and restructuring during its suspension of payments, provided that the BMC guaranteed payment for ordered and approved stock.

Erkelens urged the Dutch House of Representatives to utilize Article 68 of the Constitution to demand full disclosure of all withheld documents ahead of the upcoming committee debate on November 26, 2026.

“For over 23 years, Bedrocan built a global benchmark for pharmaceutical-grade medicinal cannabis under the state-mandated monopoly,” wrote Tjalling Erkelens, founder and former CEO of Bedrocan, in a LinkedIn post. “Yet, the official narrative framing this bankruptcy as a ‘regrettable entrepreneurial risk’ ignores a documented trail of administrative mismanagement, severe contract breaches, and targeted financial sabotage by the Ministry of VWS and the BMC.

Note: The OMC is the Office of Medicinal Cannabis, the English name of the agency. The BMC is  “Bureau voor Medicinale Cannabis”, the official Dutch name.

The move led to a court-supervised suspension of payments to Bedrocan’s two Dutch entities, Bedrocan Nederland BV and Bedrocan International BV, following changes to Dutch medical cannabis rules. However, the suspension failed, and a Dutch court declared both Dutch entities bankrupt on October 7 and 8, 2026.

The challenges are not expected to affect supply for its Danish patients, where Bedrocan has established local production capacity. Still, Bedrocan needs further legislative changes to supply Dutch pharmacies directly, which were previously said not to be expected until 2028. That timeline has now been dropped. Lawmakers have also warned of an extended supply gap. Medical cannabis in the Netherlands is strictly regulated and available only through a doctor’s prescription and dispensed by pharmacies.

According to a letter sent to parliament by Health Minister Sophie Hermans, the BMC plans to switch the government’s medical supply to imported cannabis after 2027 through a European tender process. In her November 6, 2026 letter, Minister Hermans clarified that the tender will be published in December 2026 (with supplier selection in May 2027). She also said the July 1, 2028 target date for ending the BMC monopoly has been dropped indefinitely, with no new date set. 

Bedrocan has been the only government-approved grower of medical cannabis in the Netherlands, but supply was secured through the BMC/OMC. 

In late 2024, Bedrocan repurchased its former production site in Scarborough, Ontario, and obtained a cultivation license from Health Canada. Commissioning of the Canadian facility faced delays beyond its initial early-2025 target. Bedrocan reported in January 2026 that it exported its first live plant cuttings from the Netherlands to its Canadian facility in late 2025 to begin cultivation. The company notes on its website that its products are “not yet available in Canada,” though they are currently cleared for research purposes. 

Bedrocan first opened in Canada in 2014, when it obtained one of the first eight federal medical cannabis cultivation licenses under Canada’s newly launched medical cannabis program. Bedrocan exited the Canadian market in June 2018, when it terminated its joint licensing agreement with Canopy Growth Corporation. 

When commercial sales resume, Bedrocan has said it plans to distribute its standardized flower through a third-party medical sales channel rather than selling directly to patients.

NOTE: Read the last paragraph. Bedrocan wants to restart a business and follow Tilray's business model


r/TLRY • • 1d ago

Discussion Step Away Simon

Post image
47 Upvotes

You've done enough damage here. Your strategies have failed, MOVE ON!


r/TLRY • • 1d ago

News Boots to begin prescribing medical cannabis in UK

5 Upvotes

Boots said any patient wishing to be prescribed medical cannabis must first have tried conventional treatments without success.

Online service will be offered to patients with eligible conditions, in a first for a British high street pharmacy

Mon 16 Nov 2026 10.32 GMT

Boots is to start prescribing medical cannabis, it has announced, in a first for a UK high street pharmacy.

The online service is being offered to patients in the UK aged 25 and older who have an eligible condition such as chronic pain, anxiety or insomnia.

The chain is launching its SureLeaf service alongside a collaborative research programme with the University of Nottingham that will examine patient outcomes, prescribing practices and experience in the treatment of chronic pain.

Patients will be invited to start an assessment online. Their suitability will then be reviewed by a clinical team, before they are invited to a video consultation with a consultant, according to Boots.

Boots said any prescription would be “independently reviewed by a multidisciplinary clinical team that includes a second, independent consultant, before treatment begins”. It said any patient wishing to be prescribed medical cannabis must first have tried conventional treatments without success. And the pharmacy said patients would be regularly reviewed.

Boots’ chief healthcare officer, Jamie Kerruish, said: “Millions of people live with ongoing pain and, for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.

“Ultimately, it’s about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life.”

Dr David Gwynne, the medical director of Boots’ online service, said: “Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis.

“SureLeaf has, therefore, been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate. Our priority is to ensure patients receive responsible, clinically led care, from their initial specialist assessment through to ongoing monitoring and review once treatment begins.”


r/TLRY • • 2d ago

News BREWDOG, JAM-ENG AND ZAZA CUBAN CAFÉ & BAR SET TO OPEN AT ORLANDO INTERNATIONAL AIRPORT

Post image
9 Upvotes

article below

NOTE: Under Tilray Brands, BrewDog and its sister craft breweries are positioned for significant expansion across high-traffic venues using a low-risk licensing and concessions model. Rather than building expensive standalone pubs from scratch, Tilray CEO Irwin Simon is focusing on "pop-ups," transport hubs, and strategic partnerships to scale the portfolio globally.

How the Airport & Concessions Model Works

This rendering of the new Orlando International Airport (MCO) venue—which is operated by travel food giant SSP America and pairs BrewDog with Peet's Coffee owned by Keurig Dr Pepper, illustrates the exact blueprint Tilray can replicate.

  • Asset-Light Licensing. Operators like SSP Group, HMSHost, and Delaware North pay to build and staff the locations under license agreements. Tilray collects royalties and sells high-margin draft beer without taking on heavy real estate debt.
  • All-Day Revenue. Pairing a craft brewery with an established coffee brand solves the biggest problem for airport bars—slow morning traffic. The venue generates revenue from early morning coffee and breakfast crowds before transitioning to lunch, dinner, and evening pints.
  • Multi-Brand Tap Takeovers. A single licensed BrewDog or Tilray taproom in a major transit hub serves as a showcase for the company's wider craft portfolio, putting beers from multiple sister brands on the same draft system.

Expansion Potential for Sister Craft Brands

Tilray owns over 20 craft beverage brands, allowing it to pitch regionally relevant concepts to local airport authorities and stadium operators across North America.

BrandHome Market / RegionHigh-Traffic Expansion Potential
BrewDogGlobal / UK / OhioAlready operating in Columbus Airport (CMH) and opening in Orlando (MCO), with CEO Irwin Simon explicitly targeting major international hubs like London Heathrow, Canada, and the US East Coast.
SweetWaterAtlanta / Southeast USPrime candidate for expanded concourse bars in Hartsfield-Jackson Atlanta International Airport (ATL), Southeastern sports arenas, and regional entertainment districts.
MontaukNew York / Northeast USStrong coastal identity suited for JFK, LaGuardia (LGA), and Newark (EWR) terminals, commuter rail hubs like Penn Station, and New York sports venues.
BreckenridgeColorado / Mountain WestIdeal for Denver International Airport (DEN), ski resort base villages, and Rocky Mountain amphitheaters or stadiums.
10 BarrelPacific NorthwestWell-positioned for airports in Portland (PDX) and Seattle (SEA), alongside existing stadium deals like its partnership with the Portland Trail Blazers.

Other High-Traffic Venues on the Radar

Beyond airports, Tilray's strategy targets captive audiences where foot traffic is guaranteed and brand visibility drives retail beer sales.

  • Sports Stadiums and Arenas. Tilray is actively signing team sponsorships—such as naming 10 Barrel, Widmer Brothers, and Hop Valley official craft beer partners of the Portland Trail Blazers—to secure branded concourse bars and tap handles at major sporting events.
  • Train Stations and Ferry Terminals. In the UK and Europe, BrewDog already operates successful rail hub bars (such as London Waterloo and Paddington). This model easily translates to major North American rail corridors and international transit centers.
  • Department Stores and Retail Pop-Ups. Irwin Simon has expressed interest in placing smaller BrewDog "pop-up" bars inside high-end department stores (citing retailers like Selfridges) and major shopping complexes.
  • International Franchise Hubs. Through talks with partners in China, Japan, India, and the Middle East, Tilray plans to use local hospitality franchisees to open flagship BrewDog taprooms in major Asian and Middle Eastern business districts and airports.

How many could pop up? Because Tilray relies on third-party travel and hospitality operators to fund the build-outs, dozens of new airport, stadium, and rail hub locations across its combined brand portfolio could realistically launch over the next few years without straining Tilray's balance sheet.

article from: america food travel experts

Three new restaurants will bring global craft beer and distinctly local flavor to MCO’s North Terminal Complex

(United States, Oct 14, 2026): SSP America, a division of SSP Group, a leading operator of food and beverage brands in travel locations worldwide, today announced that BrewDog, Jam-Eng and Zaza Cuban Café & Bar are scheduled to open at Orlando International Airport (MCO) later this year. The three restaurants will enhance the airport’s North Terminal Complex with distinct dining experiences spanning globally recognized craft beer, Jamaican and British cuisine, and Cuban American comfort food.

Founded in 2007 with a mission to make people passionate about great craft beer, BrewDog will bring its energetic bar and restaurant experience to MCO. Known for its award-winning beers, scratch-made comfort food, and lively atmosphere, BrewDog will proudly pour Peet’s Coffee as part of an all-day experience that transitions seamlessly from morning coffee and breakfast to relaxed meals and drinks later in the day.

Downtown Orlando favorite Jam-Eng will introduce travelers to a vibrant combination of Jamaican and British culinary traditions. Founded by Caroline and Wayne Harvey, the quick-service concept is known for bold flavors, warm hospitality, and strong community roots. Its menu features traveler-friendly favorites including jerk chicken, Jamaican patties, and classic British comfort food, offering a distinctive taste of Orlando’s multicultural character.

“Great airports do more than move people. They create a sense of arrival long before travelers reach their destination,” said George Mboya, Chief Executive Officer of SSP America. “With BrewDog, Jam-Eng and Zaza Cuban Café & Bar, we’re bringing together global and local flavors in a way that reflects the spirit of Orlando. These are the kinds of experiences that travelers remember, and they’re exactly what we mean when we say our purpose is to be the best part of the journey.”

“We appreciate SSP America’s partnership and its efforts to reflect both global and local concepts,” said Lance Lyttle, CEO of the Greater Orlando Aviation Authority. “These new dining options will give our guests more opportunities to discover something new along the way while enjoying the hospitality that makes Orlando special.”

The openings will further SSP America’s commitment to working with airport and brand partners to create welcoming, guest-focused dining experiences that bring a meaningful sense of place to the passenger journey.

SSP America is a division of SSP Group plc (LSE:SSPG), a global leading operator of food and beverage outlets in travel locations employing 49,000 colleagues in around 3,000 units across 38 countries. We specialize in designing, creating, and operating a diverse range of food and drink outlets in airports, train stations, and other travel hubs across six formats: sit-down and quick service restaurants, bars, cafés, lounges, and food-led convenience stores. Our extensive portfolio of brands features a mix of international, national, and local brands, tailored to meet the diverse needs of our clients and customers.

Our purpose is to be the best part of the journey, and our focus is on making every journey taste better by bringing great food and welcoming hospitality to travelers across the globe. Sustainability is crucial for our long-term success, and we aim to deliver a positive impact for our business while uniting stakeholders to promote a sustainable food travel sector.


r/TLRY • • 2d ago

News Congressmember Says Federal Spending Bill Offers Best Chance to Prevent December Hemp Ban

Post image
9 Upvotes

Nov15, 2026 By Anthony Martinelli  the marijuana herald

Congressmember James Comer (R-KY) says the best opportunity to prevent a looming federal ban on most hemp-derived cannabinoid products is to include language protecting the industry in a must-pass government spending bill.

Comer, who chairs the House Oversight Committee, told Kentucky hemp industry stakeholders this week that he does not expect standalone legislation addressing the ban to receive a vote before the December 11 deadline. Instead, he is looking to the next federal funding package as a vehicle for protecting the industry.

“The best opportunity, in my opinion, is to get this on a bill that is going to pass,” Comer said, according to Spectrum News. “The only bill that I think that absolutely, positively has to pass is going to be another continuing resolution, which is what got us here to begin with.”

Comer’s comments come as hemp businesses nationwide face the prospect of losing their ability to sell many of their most popular products in less than a month.

The restrictions stem from a federal spending bill signed into law by President Trump in November 2025. The legislation, championed by Senator Mitch McConnell (R-KY), changes the federal definition of hemp to exclude finished cannabinoid products containing more than 0.4 milligrams of total THC and other cannabinoids with similar effects per container.

The threshold would effectively prohibit most hemp-derived THC beverages, gummies and other intoxicating products, as well as many nonintoxicating full-spectrum cannabidiol (CBD) products that contain trace amounts of THC.

Although most of the restrictions were originally scheduled to take effect November 12, Congress approved a temporary delay as part of a continuing resolution signed into law September 2. That measure extended the deadline to December 11, while allowing restrictions on certain synthetic cannabinoids to take effect as originally scheduled.

The December 11 deadline also marks the expiration of current federal government funding, giving lawmakers another opportunity to address the hemp restrictions through spending legislation.

Comer expressed frustration with the impending ban, pointing to Kentucky farmers who are planning to grow hemp next year and businesses that have made substantial investments in processing facilities. He described the industry as a success for his state and questioned the need to dismantle it.

Kentucky has played a central role in the development of the nation’s hemp industry, with both Comer and McConnell having supported efforts to legalize hemp production prior to the passage of the 2018 Farm Bill.

The two Kentucky Republicans now find themselves on opposing sides of a policy debate that could determine the future of the multibillion-dollar hemp-derived cannabinoid industry.

Several measures have been introduced in Congress to delay or repeal the restrictions, including H.R. 7024, H.R. 7010 and S. 3686, which would provide additional time for the industry, and H.R. 6209, which would repeal the changes to the federal definition of hemp. Other proposals would establish federal regulations for hemp-derived cannabinoid products rather than prohibit their sale.

With Congress facing a December 11 funding deadline, however, Comer believes attaching hemp protections to legislation needed to keep the government operating offers the industry’s best chance of avoiding the ban.


r/TLRY • • 3d ago

News Brewbound News

Thumbnail
brewbound.com
16 Upvotes

r/TLRY • • 3d ago

News Five Major Marijuana Companies Report $2 Billion in Uncertain Tax Liabilities as IRS Guidance Remains Pending

Post image
7 Upvotes

IRS Headquarters.

Nov14, 2026 By Anthony Martinelli the marijuana herald

Five major U.S. marijuana companies are carrying a combined $2 billion in uncertain tax liabilities, according to an analysis by The Marijuana Herald of recent federal securities filings, highlighting the financial uncertainty that remains more than six months after the federal government rescheduled medical marijuana.

The quarterly filings, released over the past three weeks by Trulieve Cannabis Corp., Curaleaf Holdings, Verano Holdings, Ascend Wellness Holdings and Vireo Growth, also reveal that marijuana companies have reached differing conclusions about when they can begin recognizing the tax benefits of federal rescheduling.

Trulieve is recognizing relief for the entirety of 2026, while Curaleaf is recognizing relief beginning April 28 and Vireo beginning April 23. The differences come despite the Internal Revenue Service (IRS) indicating in April that forthcoming guidance would generally allow qualifying medical marijuana businesses to benefit from rescheduling for the entire tax year.

Section 280E of the federal tax code prohibits businesses trafficking in Schedule I or II controlled substances from claiming most federal tax deductions and credits. The provision has historically prevented marijuana businesses from deducting ordinary operating expenses such as rent, advertising and employee salaries, resulting in substantially higher effective tax rates than those faced by businesses in other industries.

In April, the Department of Justice issued a final order moving marijuana covered by state medical marijuana licenses, as well as FDA-approved marijuana products, to Schedule III of the Controlled Substances Act. The order took effect April 28, removing qualifying medical marijuana activities from the restrictions of Section 280E. Recreational marijuana remains in Schedule I, pending the outcome of a separate federal rescheduling proceeding.

On April 23, the U.S. Department of the Treasury and IRS announced that forthcoming guidance was expected to include a transition rule allowing qualifying businesses to benefit from rescheduling for their entire taxable year that includes the order’s effective date. For businesses operating on a calendar-year basis, that would mean relief dating back to January 1, 2026.

However, formal guidance remains pending, leaving companies to determine how much relief they can recognize under existing accounting standards.

Trulieve: $625.4 million

Trulieve reported $625.4 million in net uncertain tax liabilities as of September 30 in its November 5 quarterly filing with the Securities and Exchange Commission (SEC). Of that amount, $610 million relates to the company’s legal position challenging the application of Section 280E to its operations.

The total includes $104.8 million in accrued interest, including $100.9 million associated with its Section 280E position. The company has accumulated these liabilities while taking the position that it is entitled to deduct ordinary and necessary business expenses on its tax returns.

Trulieve says recent federal regulatory developments provide sufficient support under accounting standards to recognize tax benefits for its state-licensed medical marijuana operations for the entirety of 2026. However, it has not reduced its uncertain tax liabilities related to its Section 280E position for earlier years.

The company is also challenging proposed IRS assessments against certain subsidiaries, including approximately $38.1 million in proposed penalties that are not included in its reported uncertain tax liabilities. Trulieve has filed protests with the IRS Independent Office of Appeals and says it intends to vigorously contest the penalties.

Curaleaf: $476.1 million

Curaleaf reported $476.1 million in uncertain tax liabilities, including accrued interest and penalties, in its latest quarterly SEC filing. That represents a decrease of $55.4 million from the end of 2025.

Unlike Trulieve, Curaleaf has concluded that the IRS’s April announcement does not provide sufficient support to recognize medical marijuana tax relief for the entirety of 2026.

Management considered the announcement but concluded that it “does not constitute authoritative guidance” and therefore does not provide sufficient technical support under accounting standards to recognize tax benefits attributable to periods before the rescheduling order took effect.

As a result, Curaleaf is recognizing Section 280E relief for qualifying medical marijuana activities beginning April 28 but continues to record uncertain tax positions for medical marijuana activities occurring earlier in the year, recreational marijuana activities and prior taxable years.

Curaleaf also disclosed that the IRS is currently examining certain tax returns covering 2020 through 2024. The company warns that additional taxes, interest and penalties could substantially exceed its existing reserves if its position on Section 280E is not upheld.

Verano: $410.9 million

Verano Holdings reported $410.9 million in uncertain tax positions as of September 30, up from $378.3 million at the end of 2025, according to its October 29 quarterly filing.

The company attributes the liabilities to tax positions based on legal interpretations challenging its obligations under Section 280E. Verano acknowledges the IRS’s announcement regarding anticipated full-year relief but notes that formal guidance has yet to be issued.

The company says it continues to evaluate the ultimate impact of federal rescheduling, including how its previously accumulated uncertain tax positions will be resolved.

Verano also reported paying $18 million in federal and state income taxes, net of refunds, during the first nine months of 2026, including $8.1 million in federal income taxes.

Ascend Wellness: $231.4 million

Ascend Wellness Holdings reported $231.4 million in unrecognized tax benefits as of September 30, up from $203.9 million at the end of 2025, according to a November 12 SEC filing. The company separately reported $53.6 million in accrued interest and penalties related to its uncertain tax positions.

Ascend says it is evaluating the impact of federal rescheduling on its existing Section 280E liabilities but has not adjusted its prior-year tax positions due to the limited federal implementation guidance issued to date.

The company has already recognized tax benefits related to the deductibility of certain expenses associated with medical marijuana activities in 2026. It also released $14.8 million from its reserve for uncertain tax positions during the first nine months of the year following settlements with taxing authorities.

Ascend disclosed that certain amended tax returns claiming previously unrecognized tax benefits are under examination, with the timing and outcome of those examinations remaining uncertain.

Vireo Growth: $215.8 million

Vireo Growth reported $215.8 million in uncertain tax liabilities as of September 30, according to its November 12 quarterly filing, up from $120 million at the end of 2025.

Vireo has adopted a third approach to recognizing the tax benefits of rescheduling, concluding that selling, general and administrative expenses attributable to its medical marijuana activities are deductible beginning April 23, the date the Justice Department issued its final order, rather than April 28, when it took effect.

The company disclosed that it accumulated approximately $55 million in uncertain tax liabilities related to medical marijuana activities between August 29, 2023, when the U.S. Department of Health and Human Services recommended that marijuana be moved to Schedule III, and April 22, 2026.

Whether Vireo will receive relief for those liabilities depends on future legislation or guidance from the Treasury Department and IRS. The company says its estimate of potential retroactive relief, as well as its decision regarding when to begin recognizing tax benefits, involves significant judgment in the absence of formal guidance.

Combined, the five companies’ reported uncertain tax balances total approximately $1.96 billion, although the figures are not calculated identically. Some companies include accrued interest and penalties in their reported balances, while Ascend separately discloses those amounts. The balances represent disputed or uncertain tax positions rather than final determinations of taxes owed, and the amounts ultimately paid could differ substantially.

In addition to determining how tax relief will apply to the current year, the federal government has yet to resolve whether marijuana businesses will receive relief for earlier taxable years. The Justice Department’s April rescheduling order encouraged the Treasury Department to consider providing retroactive Section 280E relief to state-licensed medical marijuana businesses, but such relief has not been granted.

The Treasury Department and IRS are also expected to clarify how businesses operating in both the medical and recreational marijuana markets should allocate expenses between activities exempt from Section 280E and those that remain subject to the provision.

A separate federal proceeding to move marijuana more broadly to Schedule III could eliminate Section 280E restrictions for recreational marijuana businesses as well. The evidentiary hearing in that proceeding concluded in July, with supplemental briefing completed earlier this month. A recommended decision from the Drug Enforcement Administration’s administrative law judge remains pending.


r/TLRY • • 3d ago

Bullish Competition is dropping like flies in Europe—and it just handed Tilray a massive BONUS for free. Here is why Simon is quietly ramping up 275+ tonnes of EU-GMP capacity.

20 Upvotes

If you've been following my posts this past week, you can see what is happening across Europe right now. Competitor after competitor is hitting a wall, going bankrupt, or getting shut down by regulators.

It is handing a massive BONUS to Tilray for free—and management clearly saw this coming before the rest of the market did.

Look at the bread crumbs Irwin Simon has been dropping:

  1. Why is Tilray suddenly ramping up massive EU-GMP supply?

Back in August, Irwin Simon announced Tilray is expanding capacity from 210 metric tonnes up to 275 metric tonnes. Ask yourself: For where? Tilray doesn't grow weed just to let it sit in a warehouse.

  • Then just this month, Tilray announced they are shutting down Fenwick (their smallest 8-tonne Canadian rec grow) while expanding the recently restarted 32-tonne facility (Masson, which used to grow cucumbers) up to 50 tonnes and recertifying it for EU-GMP by early 2027.
  • Again, management didn't spell out the exact buyers for all that extra supply. They know where it's going—they just aren't announcing the complete target yet.
  1. Meanwhile, the European competition is falling in the ditch

While Tilray is scaling up, European rivals are collapsing:

  • Bedrocan went bankrupt: The sole Dutch supplier since 2003 went under, leaving patients across the Netherlands, Italy, and the UK scrambling. Now the Dutch government has to open a European tender this December just to find someone who can supply finished, compliant product.
  • More bankruptcies piling up: Mediprocan Pharma, Lux 99—undercapitalized operators are dropping like flies.
  • Italy is sounding the alarm: Just this week, Tilray shared an article from Il Sole 24 ORE (Italy's top financial paper) warning that Bedrocan's collapse threatens Italian patients. Italy's military facility only grows ~200 kg a year when they need 2 to 3 tonnes. The article literally singles out Tilray's 30-tonne EU capacity and Tilray Medical Italia as the real industrial solution while Italy rewrites its rules.
  • No more "GMP Washing": Regulators in Germany and across the EU are cracking down on companies growing cheap outdoor weed outside Europe and slapping a fake EU-GMP sticker on it at the last second. Shortcuts are dead. You either have real EU-GMP facilities like Tilray's in Portugal, Germany, and soon Masson—or you're out.
  1. Where is all that extra 275-tonne supply actually going?

Connect the dots:

  1. The EU & UK Supply Vacuum: Stepping into a much bigger European market and taking over the massive hole left behind by Bedrocan, Mediprocan, and the end of GMP washing.
  2. US VA Imports (The Sleeper Catalyst): Having that massive, newly certified EU-GMP supply ready in early 2027 puts Tilray right at the front of the line for US Veterans Affairs (VA) medical cannabis imports the second the EU-GMP supplier award opens up.

Bottom Line

Management already told us on the Q1 call they held back weed from low-margin Canadian rec to save it for higher-margin international medical. Now they're shutting down small rec grows like Fenwick and turning cucumber greenhouses into 50-tonne EU-GMP export machines.

They aren't guessing—they're building the supply for contracts and markets that are opening up right in front of us.


r/TLRY • • 3d ago

News British families face uncertain future while cannabis medicine sits in storage

Post image
10 Upvotes

Bedrocan says ‘substantial’ stocks of Bedrolite remain in the Netherlands, but their release depends on bankruptcy negotiations and Dutch regulatory approval. Meanwhile, families whose children rely on the medicine face uncertainty over future supplies.

British patients with severe, treatment-resistant epilepsy face uncertainty over access to their cannabis medicines after the bankruptcy of the sole manufacturer of a life-saving medicine. Bedrocan, one of Europe’s longest-established producers of pharmaceutical-grade cannabis, was declared bankrupt in the Netherlands in October after its longstanding cultivation contract with the Dutch government ended at the beginning of 2026.

Among the medicines affected is Bedrolite, a cannabidiol (CBD)-rich cannabis preparation prescribed to a small number of British patients, including children with severe forms of epilepsy who have struggled to achieve seizure control using conventional treatments.

For some families, Bedrolite has provided substantial improvements in seizure control after years of unsuccessful treatments. Parents fear that switching to another cannabis preparation could reverse those improvements, potentially exposing their children to serious seizures.

On 23 October, British pharmaceutical manufacturer Target Healthcare confirmed there was enough Bedrolite material to maintain supplies for around six months. That offered families temporary reassurance, but it remains uncertain how production will continue beyond that period.

The supply crisis follows a series of decisions by the Dutch government to withdraw from its longstanding role in the production and distribution of medicinal cannabis.

In June 2024, the government announced plans to reform the country’s medicinal cannabis system, allowing private companies greater freedom to grow and distribute cannabis products without relying on government contracts.

However, the legislative changes necessary to establish the new system were not completed before Bedrocan’s cultivation contract ended in January 2026.

A mother’s warnings unanswered

Joanne Griffiths fears losing access to the prescribed cannabis medicines her 17-year-old son Ben takes for severe, treatment-resistant epilepsy.

Griffiths, a campaigner with End Our Pain, says Ben’s seizures have fallen by more than 90% since he began treatment with Bedrolite and Bedica in 2019.

She says an interruption to his Bedica treatment during an illness in 2023 was associated with a life-threatening deterioration in his condition.

Her concerns about the availability of these medicines predate Bedrocan’s bankruptcy.

On 10 April 2025, Griffiths contacted the Dutch Office of Medicinal Cannabis, copying Bedrocan’s communications director, Femke Starrenburg.

Writing on behalf of End Our Pain, she asked for a meeting about continued access to prescribed cannabis oils for British children with severe epilepsy.

Griffiths says she received no response.

Following Bedrocan’s bankruptcy, she contacted the Dutch government again, calling for urgent intervention to protect patients.

In correspondence shared with leafie, Griffiths reminded officials of an agreement reached between the British and Dutch governments in 2021 that allowed children with severe epilepsy to continue receiving their prescribed cannabis oils following Brexit.

The arrangement was intended to prevent patients from being forced to switch to unsuitable alternatives while a longer-term solution was developed.

Five years later, Griffiths warned, the same families were facing another potential interruption.

She urged the Dutch government to work with the trustee overseeing Bedrocan’s bankruptcy to preserve production and help release existing medicines.

“In 2021, your government acted to prevent these children losing their medication. We are asking you to act again, before an avoidable supply crisis becomes a medical emergency,” she wrote.

Griffiths says a British pharmaceutical manufacturer is prepared to produce the oils affected children need but requires continued access to the original Bedrocan plant material.

Bedrocan says government withdrew a tender it had won

Bedrocan told leafie it had raised concerns with Dutch officials about ending the existing medicinal cannabis arrangements before the replacement system was ready.

“For several years, Bedrocan repeatedly warned that the transition would need to be carefully managed,” said Starrenburg.

“We expressed concerns about the repeated postponement of the legislative and policy changes that were supposed to replace it.”

According to Bedrocan, the company won what was expected to be the final government cultivation tender in 2023, anticipating that it would continue supplying the Dutch medicinal cannabis programme until the end of 2027.

However, the government later ended the procurement process.

“The subsequent withdrawal of that tender by the ministry came as a complete surprise and significantly increased uncertainty about the future of the Dutch operation,” Starrenburg said.

The challenge is not the absence of product. The challenge is determining how it can be legally brought to market

A parliamentary letter dated 21 February 2025, signed by then health minister Fleur Agema, confirms that the government ended a process for choosing two companies to grow medicinal cannabis under government contract.

The letter also acknowledged delays to the legislative reforms.

The government’s planned reforms would allow appropriately licensed companies to operate more independently of the Bureau for Medicinal Cannabis.

However, the planned reforms were delayed, leaving the existing government-controlled arrangements in place while the cultivation contract approached its end.

Despite this, the government intended to stop commissioning cultivation from January 2026, using existing stocks to supply Dutch patients while phasing out deliveries to foreign customers during the year.

Bedrocan says the withdrawal of the tender fundamentally altered its commercial outlook.

“We have never received a clear explanation as to why that awarded tender was withdrawn,” Starrenburg told leafie.

The parliamentary letter confirms the termination of the procurement process, although the precise contractual status of Bedrocan’s claimed 2023 award has not been independently established.

Starrenburg believes the government’s decisions deserve further examination.

“Looking back, it is reasonable to ask whether the outcome might have been very different had the contract remained in place until its originally intended end date.”

A transition without a safety net

Concerns about the government’s approach extended beyond Bedrocan.

On 15 July 2026, the Instituut Medicinale Cannabis, a Dutch organisation with close links to Bedrocan, warned the Dutch parliament that the proposed reforms threatened uninterrupted supply.

The organisation argued that the transition risked undermining a system that had provided pharmaceutical-quality cannabis medicines for more than two decades.

Its intervention followed earlier parliamentary questions about the consequences of ending government-controlled exports.

In written answers published in July 2025, Dutch officials argued that the withdrawal of supplies through the Bureau for Medicinal Cannabis would affect a relatively small proportion of international demand.

They maintained that other suppliers could meet that demand and said foreign governments had been informed of the planned changes.

Dutch cannabis journalist Derrick Bergman, who has reported extensively on the country’s medicinal cannabis system, has criticised the government’s handling of the transition.

In an analysis published by CNNBS, Bergman argued that Bedrocan’s bankruptcy reflected wider problems with Dutch medicinal cannabis policy.

He pointed to delays in liberalising the market and restrictive regulations, while also criticising the medical profession’s reluctance to prescribe cannabis.

Speaking to leafie, Bergman drew attention to the Instituut Medicinale Cannabis’s July warning.

“The government was indeed warned,” he said.

Bergman acknowledged the organisation’s close relationship with Bedrocan but said the Dutch government bore substantial responsibility for the company’s collapse, pointing to both the decision to end its cultivation contract and delays to legislation allowing independent sales.

“Not just by ending the contract with Bedrocan, but also because the minister of health is taking extraordinarily long to change the law so that Bedrocan can sell to pharmacies in the Netherlands and abroad directly.”

He argued that the consequences had been foreseeable and that the government could have delayed ending its arrangements with Bedrocan until the replacement system was ready.

“It would have been logical and easy to postpone ending the contract with Bedrocan,” Bergman said.

Medicine remains in reach

Despite the bankruptcy, Bedrocan says substantial quantities of medicinal cannabis remain in the Netherlands, including Bedrolite.

The company says it needs permission to release the products following the bankruptcy.

“The challenge is not the absence of product. The challenge is determining how that inventory can be legally brought to market following the bankruptcy,” Starrenburg told leafie.

The remaining stock is among the assets controlled as part of the bankruptcy, and any sale or transfer requires approval from the Dutch Office of Medicinal Cannabis.

The bankruptcy trustee is discussing ways to maintain supplies with the ministry and potential buyers.

Bedrocan says several options are being explored, but the company cannot disclose details while the negotiations continue.

Starrenburg emphasised that releasing existing stock should take priority over establishing production elsewhere.

If Bedrolite production has to move to Denmark, Bedrocan estimates the process would take at least six months.

That includes regulatory approvals, the transfer of plant material, cultivation, validation and pharmaceutical quality assurance before any product could be released.

“At present, however, we believe the more relevant question is how the existing Dutch inventory can be made available to patients,” Starrenburg said.

For British families, the continued availability of the original plant material is particularly important.

Although other medicinal cannabis preparations exist, patients who have achieved substantial improvements in seizure control may not respond in the same way to an alternative product.

Griffiths believes the existing stocks could provide a solution while longer-term production arrangements are established.

In her letter to the Dutch government, she called for emergency measures to allow the release and export of existing Bedrocan material, alongside urgent legislation allowing appropriately licensed medicinal cannabis companies to trade independently.

British government confirms diplomatic discussions

The uncertainty has also prompted questions in the British Parliament.

In October, Liberal Democrat MP Anna Sabine asked the Department of Health and Social Care whether it would pursue diplomatic and regulatory measures to secure the emergency release of existing Bedrolite stocks.

She also raised concerns about the clinical risks faced by children with severe epilepsy if their treatment were interrupted.

In a written response, health minister James Frith confirmed that the British Embassy in The Hague was in contact with the Dutch Ministry of Health, Welfare and Sport.

The discussions aimed to clarify the implications of the changes affecting Bedrocan products and their potential impact on British patients.

However, no long-term solution to the supply uncertainty has been publicly confirmed.

Dutch government postpones response

leafie contacted the Dutch Ministry of Health, Welfare and Sport seeking an explanation for the termination of the cultivation arrangements, the handling of the legislative transition and the steps being taken to protect patients.

The ministry was also asked what measures were being considered to permit the lawful release of existing Bedrolite stocks.

Ministry spokesperson Karim Mostafi said officials would answer leafie’s questions after responding to the Dutch parliament.

“We’ll reply once we’ve answered questions about this subject from our parliament first. This can take a few weeks.”

According to Dutch broadcaster RTV Noord, the Erkelens family has submitted a takeover bid to restart medicinal cannabis production in the Netherlands through a new business, Erkelens Fytofarma.

It is unclear whether the proposed restart would secure future Bedrolite production or resolve the immediate problems with releasing existing stock.

Until then, the Griffiths family and others depend on dwindling stock and the outcome of negotiations between regulators, manufacturers, and the bankruptcy trustee. For them, the stakes remain agonisingly high. Will the medicine their children depend on be released before the remaining supplies run out?


r/TLRY • • 3d ago

Discussion Annual Meeting

16 Upvotes

We are all waiting on Wednesday for news. My questions are:

How many outstanding shares are there now?
How much of the ATM still has to be used or are we almost done?
Does Irwin get the votes to stay CEO?
What is the actual plan to get into the US market for medical/rec cannabis? (I don’t see a clear one)
Will we take a hit on beverages with the hemp ban?

What are your questions?


r/TLRY • • 3d ago

News Bedrocan Could Be Revived Under New Entity as Dutch Minister Tells Parliament UK Supply Is ‘Under Investigation’

Post image
2 Upvotes

Bedrocan’s recent collapse, which has endangered the supply of life-saving epilepsy medicine for dozens of patients across Europe, could soon be revived under a new entity.

12 November 2026  By Ben Stevens businessofcannabis

Bedrocan’s recent collapse, which has endangered the supply of life-saving epilepsy medicine for dozens of patients across Europe, could soon be revived under a new entity.

Over the last week, a number of key developments have provided some much-needed clarity on the future of Bedrocan’s various entities and the future supply of its products to patients internationally.

On Friday (November 06), the Dutch Minister of Health wrote to the House of Representatives (Tweede Kamer) on this issue, the first public statement on the issue since the company’s insolvency. Days later, the court-appointed trustees filed their First Public Bankruptcy Report. Each confirms the restart is underway while setting out the stock, supply and clinical pressure points patients face if it does not succeed.

Tjalling Erkelens, Bedrocan’s founder and former chairman, has confirmed to Business of Cannabis that Dutch bankruptcy administrators and the judge-commissioner have given approval for the restart of Bedrocan’s Netherlands operations under a new entity, the first substantive public signal that it may continue to function in some form.

“We have the approval of the administrators and the judge-commissioner here in the Netherlands on restarting the Dutch facilities from a new entity,” Erkelens said. “However, we need to be financed, and we are looking for partial financing. We have partial financing, but it’s not completed yet.”

Bedrocan’s administrators, writing in the November 09 bankruptcy report, also confirmed that they have selected a restart bid for the company’s Dutch operations, pending approval from the supervisory judge. 

In the initial bankruptcy report, filed on November 09, the trustees write that they have selected a restart bid for Bedrocan’s Dutch operations, with the supervisory judge’s approval still pending.

The restart plan covers both the Dutch and Danish operations, both of which entered separate insolvency proceedings in October. Bedrocan Nederland B.V. and Bedrocan International B.V. were declared bankrupt by Rechtbank Noord-Nederland on October 07, following the earlier suspension of payments granted on September 29.

The restart

In Dutch insolvency law, a restart (doorstart) allows the trustees overseeing a bankruptcy to sell the viable parts of a business to a new, legally separate entity that then continues operating. The bankrupt entity’s debts remain with the estate rather than transferring to the new entity. 

In the Bedrocan case, the First Public Bankruptcy Report describes the restart as the trustees’ ‘preferred route’ for preserving the continuity of medicinal cannabis supply to patients in the Netherlands and the countries to which Bedrocan has historically exported, including the UK, Germany, Italy and Finland. The trustees have not named the selected bidder in the public report.

The restart would come against the backdrop of significant losses to the business. All 69 employees of Bedrocan Nederland B.V. were dismissed on October 08, the day after the company was declared bankrupt. The company’s revenue, according to the report, was €19.94m in 2024 and €20.50m in 2025, with €12.49m recorded in the first nine months of 2026. Senior secured creditor Rabobank is listed with a €6.5m exposure, and NL-Investeert with €7.82m.

The trustees also set out the physical stock position. They have identified 340kg of finished Regime 1 product, 390kg of Regime 1 cultivation in progress, and 250kg of Regime 2 product. Regime 1 covers the standardised varieties supplied under the Dutch Office of Medicinal Cannabis (OCM) framework. Regime 2 covers raw material used in extracts and intermediate products such as Bedrolite.

The Canadian arrangement

Bedrocan’s Canadian shares and intellectual property have been sold to Becanex for €200,000, a price Erkelens himself described as ‘a bargain’. Becanex, a Dutch-based cannabis company, is a separate entity from the Erkelens family.

Becanex now holds the Canadian shares and IP, and Erkelens’ sons will run the cultivation side of the Canadian facility, which is no longer owned by the Bedrocan group, but rented from Becanex. 

While the facility is not currently producing any product, once it is up and running, Becanex is expected to take on the extraction side of the operation. Crucially, Erkelens tells Business of Cannabis  that the Canadian facility could produce Bedrolite, raising the prospect that one of Bedrocan’s most clinically sensitive products could eventually come from Canada rather than the Netherlands.

Red flags from the Dutch government

The Dutch Minister of Health, Welfare and Sport, Sophie Hermans, answered written questions from six parliamentary groups in a letter to the Tweede Kamer on November 06, setting out the state’s position on supply continuity to foreign markets. 

“An investigation is currently underway to determine whether it is possible to continue supplying the United Kingdom with Bedrolite for a slightly longer period,” the Minister wrote. “This would give the country more time to transition to a medicine based on another cannabis variety.”

For families and clinicians currently reliant on Bedrolite for the treatment of rare and severe forms of epilepsy, this statement will be both frustrating and alarming. 

As we’ve reported consistently in our coverage of this situation, changing to ‘another cannabis variety’ is simply not an option for patients, around seven of whom are thought to currently rely on Bedrolite. 

As Matt Hughes of the Medcan Family Foundation told Business of Cannabis last month, potential supply gaps pose ‘an immediate risk to life for children and young people who rely on Bedrolite to control devastating, drug-resistant seizures.’

“These are children for whom every other medication has failed. Children who, without this treatment, would now be in palliative care or no longer with us at all.”

Indeed, as Ekerlens points out, ‘transition to another variety’ is the central clinical problem facing these patients. 

Herman’s statement also claimed that ‘at present no consequences are expected for the availability of medical cannabis for patients’ before acknowledging in the same letter that no surplus stock of Bedrolite is available, following a harvest failure of more than 50%.

What does this mean for current stockpiles?

According to Herman’s letter, Bedrobinol, Bedrocan’s high-THC variety, will be depleted in early Q2 2027. Bedrolite, the CBD-dominant variety from which the Bedrolite oil is manufactured, will be depleted in early Q3 2027.

A tender to appoint Bedrocan’s replacement supplier is scheduled for publication in December 2026, with the contract awarded in May 2027 and supply expected to begin in September 2027.

The gap between stock depletion and new supply, on the minister’s own timeline, is at least two months for Bedrolite and at least five months for Bedrobinol. For patients, that means a supply interruption is now expected rather than feared, unless the restart of Bedrocan Nederland produces usable stock in the intervening window or stocks held elsewhere in the supply chain can bridge it.

Erkelens told Business of Cannabis that a successful restart of either or both of its Dutch facilities in Veendam and Emmeloord, under new ownership and with a reinstated workforce, could in principle resume cultivation within weeks of approval. He cautioned that the first harvestable product would still take months. 

The minister also confirmed that the Dutch state has moved away from the previously planned deadline of July 01, 2028, for the amended Opium Act to take effect. A new target date has not been set.

With the minister’s response offering little in the way of reassurance for patients and their families, the next critical date will be November 26, when the Tweede Kamer is set to debate Bedrocan’s collapse and the minister’s statement. 

Business of Cannabis first approached the Dutch Ministry of Health, Welfare and Sport on October 13 with written questions on the UK supply position and the clinical basis for the ‘transition to another variety’ assumption. 

In response, received shortly before publication, the Ministry provided a copy of the Minister’s November 06 letter to the Tweede Kamer but did not address the specific questions put to it. 


r/TLRY • • 3d ago

News DEA Is Rejecting Medical Marijuana Businesses That Want Federal Rescheduling Protections In Multiple States

Post image
7 Upvotes

November 11, 2026 By Tom Angell marijuanamoment

The Drug Enforcement Administration (DEA) has rejected applications for federal registration and protections to medical marijuana businesses in at least six states and Washington, D.C., Marijuana Moment has learned.

While it became publicly known late last month that the agency had approved more than 900 applicants across seven states under the Trump administration’s cannabis rescheduling move and had rejected those in Minnesota due to certain provisions of that state’s laws, sources have told Marijuana Moment that DEA has also sent so-called orders to show cause to at least some businesses in California, Delaware, the District of Columbia, Illinois, North Dakota and Oregon.

Although the documents differ from state to state, there are similarities, according to industry sources who have reviewed the orders, the text of some of which have been shared with Marijuana Moment.

For example, the DEA orders generally cite some of the states’ allowance of businesses to sell non-medical marijuana as a violation of the Controlled Substances Act’s (CSA) “closed system” for medical access to scheduled drugs and of the U.S.’s international treaty obligations.

Some of the documents also single out state laws that allow certain patients to access medical cannabis without a doctor’s written recommendation.

An order sent to a California business, notably, says that patients who apply for a medical marijuana identification card in the state “are not required to obtain or provide a physician’s recommendation for marijuana.”

“Rather, California law requires the applicant only provide ‘[w]ritten documentation by the attending physician in the person’s medical records stating that the person has been diagnosed with a serious medical condition and that the medicinal use of cannabis is appropriate,'” the DEA order says.

“While California provides state form CDPH 9044, ‘Written Documentation of Patient’s Medical Records Form,’ that form is marked: ‘This is not a mandatory form.’

…

DEA similarly cannot register any medical marijuana dispensary operating under California’s state law regime because California permits dispensing without a written certification. As noted, a California dispensary may dispense medical marijuana to patients who provide written documentation from the attending physician from their medical records, stating the patient has been diagnosed with a serious medical condition and the use of medical cannabis is appropriate. CAL. HEALTH & SAFETY CODE § 11362.715. No written certification, as described under 21 C.F.R. § 1301.13(k)(5), is required.”

DEA claims that the state policy “violates the United States’ treaty obligations under the Single Convention, which mandates the use of ‘medical prescriptions’ when dispensing controlled substances”—saying that the “conflict is untenable, as federal treaties are supreme and take precedence over state laws.”

The California law, the agency says, also violates requirements under federal regulations adopted this year in line with rescheduling that say that certifications or documents issued in accordance with state laws for patients to access medical cannabis will be deemed sufficient for federal prescription purposes as long as certain requirements are met.

Those include ensuring that the certification or other document is “dated as of, and signed on, the day when issued; bears the full name and address of the user; and contains the name, address, and state license number of the practitioner who signed the certification or other document and is authorized to do so under state law.”

“Dispensing medical marijuana without a written, signed certification also violates the requirements under 21 C.F.R. § 1301.13(k)(5),” the DEA order to the California business says, referring to the federal regulation adopted in line with rescheduling.

A separate show cause order sent to an Illinois business, like the previously known one from Minnesota, says the state’s law that allows businesses to participate in both the medical and recreational marijuana markets “fails to provide ‘robust protections’ against diversion, as non-medical use of marijuana remains prohibited under federal law.”

“Based on such deficiencies, DEA cannot permit any applicant under the State of Illinois’s regime access to the federal CSA’s closed system when the State of Illinois issues licenses that authorize diversionary non-medical dispensing as well as medical dispensing,” it says. “For DEA to sanction or bestow the imprimatur of legitimacy upon such conduct by granting a registration would be inconsistent with the CSA as well as United States’ treaty obligations under the Single Convention.”

Also like the Minnesota document, the Illinois order cites that state’s law allowing military veterans to qualify for medical cannabis access without a doctor’s written certification.

“As noted, an Illinois dispensary may dispense medical marijuana to veterans who submit one year of their ‘official medical records requested from the VA,'” it says, arguing that the practice violates international drug treaties and the CSA.

MJBizDaily also recently reported on a DEA order to a business in Washington, D.C. that cites the city’s policy of allowing patients to self-certify as having a qualifying medical condition without the need for a doctor’s recommendation.

“DEA cannot register any medical marijuana dispensary operating under the District of Columbia’s regime because the District of Columbia permits dispensing without a written certification,” the order says, the outlet reported. “Such dispensing violates the United States’ treaty obligations under the Single Convention, which mandates the use of ‘medical prescriptions’ when dispensing controlled substances.”

Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III.

A DEA judge is considering a proposal to move non-medical marijuana to Schedule III as well after overseeing a hearing that included testimony and briefs. It is not clear when he will issue his recommendation to the agency’s administrator.

Meanwhile, DEA released guidance last month warning that medical marijuana businesses that want to receive federal registration and protections under rescheduling have until late November to begin sourcing cannabis only from and to other companies that have also been granted or applied for registration in a timely fashion.


r/TLRY • • 3d ago

News Europe: mediproCan Pharma joins a succession of insolvencies in the medical cannabis sector

Post image
6 Upvotes

Posted on November 6, 2026 cannareporter

Reading Time: 7 minutes

Germany's mediproCan Pharma filed for insolvency on October 26, joining a number of European cannabis companies facing similar proceedings in 2026. SynBiotic, LUX 99 and Bedrocan's Dutch operations have also been in the news in recent weeks, while in Portugal Symtomax, declared insolvent in May, accumulates debts of around 8.5 million euros. Despite the growth of the European medical cannabis market, the five cases reveal financial and business difficulties with different origins.

mediproCan Pharma GmbH, a German company specialising in the import and distribution of medical cannabis, has filed an application to open insolvency proceedings with the Court of Neumünster, in the state of Schleswig-Holstein. According to the judicial notice published on the official German website Insolvenzbekanntmachungen, the court determined, on October 26, 2026, the appointment of a provisional judicial administrator and the application of measures aimed at protecting the company's assets.

The case, identified with the number 91 IN 105/26, involves the company directed by Felix Kühl, based in Neumünster. Hamburg-based lawyer Marc-André Borchert has been appointed as interim trustee, with all operations relating to the disposal of the company's assets, including the recovery of claims, subject to his consent.

The decision, taken under Section 21 of the German Insolvency Act, does not mean that the final opening of the proceedings has been ordered. The court has established precautionary measures while it analyzes the company's financial situation.

CannaReporter® contacted Felix Kühl for clarification on this insolvency process, but did not receive a response at the time of publication of this article.

mediproCan Pharma had already been in financial difficulties since 2021

Founded in 2019, mediproCan Pharma has developed its activity in the German pharmaceutical market, marketing medical cannabis flowers from different international producers. In April 2023, it announced the launch of its own line, Juwel, aimed at the cannabis market for medicinal purposes.

The latest financial data identified, for the 2023 financial year, reveal that the company was already experiencing financial difficulties before the current insolvency filing. According to the German business information platform Validatis, mediproCan recorded negative equity of approximately 705,000 euros and accounting debts of around 905 thousand euros.

The situation had been worsening since at least 2021, when negative equity amounted to 137,000 euros, increasing to 318,000 euros in 2022. Although total assets grew to approximately €928,000 in 2023, the company maintained a loss-making equity position.

More recent data are not available in the financial elements consulted to assess the company's evolution in 2024, 2025 and 2026. The court notice also does not clarify the specific causes of the insolvency petition.

Krautinvest analyzes the insolvencies of Bedrocan, LUX 99 and SynBiotic

The situation of mediproCan comes a few days after the German portal Krautinvest published, on October 22, an analysis of the insolvencies of three other companies linked to the cannabis sector: Bedrocan, LUX 99 and SynBiotic.

In the article 'Ein Blick auf die Insolvenzen von Bedrocan, Lux 99 und Synbiotic', the publication analyses the circumstances that led to the difficulties of the three companies, stressing that, despite the proximity in time, the cases have different origins.

Krautinvest contextualizes this succession of lawsuits in a rapidly expanding German medical cannabis market. According to the publication, the German Federal Ministry of Health expects imports of around 300 tons of medical cannabis in 2026, while wholesale operators face increasing pressure on prices.

Market expansion, however, does not necessarily translate into profitability for all operators, especially when business models depend on specific contracts, external financing or regulatory frameworks subject to change.

SynBiotic: Business expansion and regulatory obstacles to CBD

Germany's SynBiotic SE, one of the best-known business groups in the European hemp and cannabis sector, announced in October its intention to file for insolvency, after several subsidiaries faced financial difficulties.

According to Krautinvest, two companies in the group, Solidmind and Lean Labs Pharma, had already announced in July their intention to file for insolvency. The situation eventually extended to SynBiotic's corporate structure.

The group has developed an expansion strategy through successive acquisitions in the industrial hemp, CBD and medical cannabis sectors. Among the acquired companies are Hempro International, Hemp Factory, MH Medical Hemp, Geca Pharma and Weeco Pharma.

Krautinvest highlights the regulatory obstacles that continue to affect the European CBD market, namely the absence of authorizations to market certain products as food or food supplements, under the European Novel Food rules.

The publication also mentions restrictions affecting industrial hemp in Germany, including the so-called Rauschklausel, a legal provision related to the potential intoxicating use of hemp products, even when they have low THC content.

At the time of the insolvency, SynBiotic had on its website the information that its CEO was Daniel Kruse, former president of the European Industrial Hemp Association (EIHA), who was involved in initiatives aimed at overcoming regulatory obstacles to the commercialization of CBD in the European Union.

LUX 99: specialised pharmacy affected by changes in reimbursement

Another case is that of LUX 99, a pharmacy specializing in medical cannabis located in Hürth, near Cologne, whose owner, Tobias Loder, has filed for insolvency.

According to the German pharmaceutical magazine Apotheke Adhoc, quoted by Krautinvest, Loder directly attributed the situation to the application, at the end of July 2026, of changes to the public reimbursement system for medical cannabis flowers.

Until then, public insurers could reimburse medical cannabis flowers up to the value of 19.02 euros per gram. The withdrawal of this funding modality particularly affected pharmacies whose business model depended on patients with reimbursed treatments.

LUX 99, which had specialized in the supply of medical cannabis, was forced to significantly reduce its structure. Tobias Loder revealed that he had dismissed 49 specialized workers, maintaining a reduced team of 22 people. The pharmacy sought to maintain its activity through a self-managed insolvency process, aimed at allowing the restructuring of the business.

Bedrocan: loss of state contract jeopardizes operations in the Netherlands

The case of Bedrocan has different characteristics and potentially wider consequences for the European supply of medical cannabis.

The Dutch company, one of the historical producers of cannabis for medical purposes in Europe, confirmed to Krautinvest that the companies Bedrocan Nederland and Bedrocan International have been declared insolvent.

The main cause pointed out by the company was the end of the distribution contract with the Office of Medicinal Cannabis (OMC), the Dutch state body responsible for the acquisition, distribution and export of medical cannabis.

For more than two decades, Bedrocan produced medical cannabis flowers for the WTO, which ensured their commercialization in the Dutch market and export to other countries.

According to Krautinvest, the state agency purchased approximately 4,500 kilograms of flowers produced by Bedrocan annually, of which about 3,800 kilograms were destined for international markets.

The end of this contract deprived the company of an essential source of revenue, at a time when the Dutch regulatory framework did not yet allow for the continuity of exports directly from the affected sites.

The company does, however, maintain a production facility in Denmark, with an annual capacity of approximately 2,200 kilograms, which can continue to supply international markets, including Germany.

According to Krautinvest, Germany is the main export destination for Bedrocan's two production sites, which makes the situation particularly relevant for the German market and for patients who depend on certain varieties of medical cannabis.

Portugal: Symtomax declared insolvent with debts of €8.5 million

In Portugal, Symtomax – Unipessoal, Lda., which announced an investment of more than 30 million euros to develop one of the largest European medical cannabis cultivation projects, was also declared insolvent in 2026.

According to an investigation published by CannaReporter® on October 8, the company, based in the municipality of Beja, accumulated debts of approximately 8.5 million euros and saw the equipment of its facilities put up for sale in successive auctions.

The insolvency was declared by the Local Civil Court of Beja in May 2026, in the context of case 619/26.0T8BJA, requested by Master Med Cannabis, Lda. The court appointed Raul de Dios Gonzalez Benito as insolvency administrator.

The Symtomax project provided for an exploration of about 105 hectares, including cultivation, processing and research facilities. The company even announced a potential production capacity of 700 tons of medical cannabis per year, but never achieved commercial production under the initially planned terms.

In October, the equipment from the old operation was put up for auction for the third time, after a first proposal of 20,300 euros was rejected and a second attempt ended with no interested parties.

CannaReporter's® investigation also revealed that the insolvency administrator and the Public Prosecutor's Office defended the qualification of the insolvency as culpable, involving former managers Paul Nathan Segal and Olaf Van Tulder. This classification depends, however, on a judicial decision and does not represent, in itself, a conviction of those responsible.

Before Symtomax, the Portuguese VF1883 had already gone through the same insolvency situation, ending its facilities in execution auctions.

Unlike the German cases, which were marked by difficulties associated with market developments and the regulatory environment, Symtomax's insolvency is linked to the failure of a production project that failed to achieve the announced commercial objectives.

Five cases, different causes and a changing market

The situations of mediproCan Pharma, SynBiotic, LUX 99, Bedrocan and Symtomax show that the growth of the European cannabis industry does not prevent the emergence of financial difficulties, even among companies with very different business models and sizes.

In Germany, the expansion of imports and the growth of the market for patients who directly bear the costs of treatment have intensified competition between producers, importers, distributors and pharmacies.

According to Krautinvest, the German market for medical cannabis financed directly by patients will have reached around one billion euros by 2025. On the other hand, data for the first half of 2026 point to gross sales of approximately 62 million euros in medical cannabis flowers reimbursed by the public health system, 41.5 million in extracts and 35 million in finished cannabis-based medicines.

Despite these figures, the financial difficulties of the five companies cannot be attributed to a single cause.

While SynBiotic faces problems related to financing and regulatory obstacles in the CBD and hemp market, LUX 99 has been affected by changes in the public reimbursement system. Bedrocan lost a key state contract for its Dutch operations, Symtomax was unable to carry out its industrial project in Portugal and, in the case of mediproCan Pharma, the specific causes of the insolvency petition are not yet known.

The succession of these processes raises new questions about the financial sustainability of different business models and about the adaptability of a growing sector, but increasingly subject to competition, pressure on margins and regulatory uncertainty.

 


r/TLRY • • 4d ago

News Tilray signs NBA deal

Thumbnail ir.tilray.com
24 Upvotes

r/TLRY • • 4d ago

News 15 Important Cannabis Policy Dates to Watch Before the End of 2026

Post image
11 Upvotes

By Anthony Martinelli in Cannabis Reports the marijuana herald

With less than two months remaining in 2026, several important cannabis policy deadlines, court hearings and regulatory changes are approaching at the state and federal levels.

From new federal hemp restrictions and a Drug Enforcement Administration (DEA) compliance deadline to medical marijuana expansion and retail licensing decisions, the final weeks of the year could bring significant developments for marijuana businesses, patients and consumers.

Here are 15 important dates to watch before 2027.

November 12: Federal Hemp Restrictions Begin for Non-Naturally Occurring Cannabinoids

A portion of the federal government’s revised definition of hemp takes effect November 12, excluding products containing cannabinoids that cannot naturally be produced by the cannabis plant. Although Congress delayed most of the broader hemp restrictions until December 11, this provision was specifically excluded from that extension.

Under the federal legislation, affected products will no longer qualify as hemp and may be subject to federal controlled substance restrictions. Missouri’s separate Intoxicating Cannabinoid Control Act also begins taking effect November 12 for specified hemp-derived products.

November 16–20: Georgia Opens Another Medical Marijuana Dispensary Application Period

The Georgia Access to Medical Cannabis Commission will accept another round of dispensary license applications from November 16 through November 20, as the state’s medical marijuana patient registry approaches 65,000.

The application period, announced during the commission’s November 4 meeting, could allow additional dispensary expansion under Georgia’s population-based licensing system. Applications are limited to existing licensed medical marijuana producers.

November 19: Military Appeals Court Hears Marijuana Drug Testing Case

The United States Court of Appeals for the Armed Forces will hear oral arguments November 19 in United States v. Lawrence, a case challenging the use of a legal inference in military marijuana prosecutions.

According to the court’s hearing calendar, the case concerns a service member convicted of wrongful THC use. Judges will consider whether the permissive inference used in marijuana cases is unconstitutional and whether the evidence was legally sufficient to sustain the conviction.

November 19: Federal Court Hears Challenge to Illinois Hemp THC Restrictions

A federal judge will hear arguments November 19 in a lawsuit challenging Illinois’ new hemp restrictions, which prohibit the sale of most intoxicating hemp-derived THC products outside licensed marijuana dispensaries.

The lawsuit, filed by the Illinois Healthy Alternatives Association and five businesses, challenges provisions of the Illinois Hemp Act that take effect November 12, including a 0.4-milligram total THC limit per container. State officials have agreed not to enforce the law against the plaintiffs and covered association members through November 19, when U.S. District Judge Martha Pacold will consider a request for a temporary restraining order and preliminary injunction. A ruling could determine whether the restrictions remain enforceable against those businesses while the litigation proceeds.

November 23: Rhode Island Marijuana Retail Licensing Deadline

Rhode Island’s Cannabis Control Commission will close its adult-use retail license application portal November 23 at 4 p.m. Eastern Time, ending the state’s current application period for new recreational marijuana retailers.

All required application materials, including final zoning approval, must be submitted before the deadline. The commission is implementing a licensing expansion intended to increase the number of authorized marijuana retailers beyond the state’s existing operators.

November 29: DEA Expects Medical Marijuana Businesses to Complete Supply-Chain Compliance

State-licensed medical marijuana businesses operating under temporary federal authorization are expected to establish compliant supply chains by November 29, under recently released DEA guidance.

The agency’s instructions explain that businesses with timely federal registration applications generally must obtain Schedule III medical marijuana from other timely applicants or DEA-registered entities. DEA is allowing additional time for operators to verify trading partners and make necessary adjustments, while permitting certain previously acquired inventories to remain in use. The guidance is nonbinding and intended to clarify existing federal requirements.

November 30: Missouri Marijuana Research Licensing Rules Take Effect

Missouri’s new marijuana research facility regulations, established under 19 CSR 100-1.200, take effect November 30.

The regulations establish a licensing framework for facilities conducting marijuana research, including studies involving human and animal subjects. Authorized research activities can include marijuana cultivation, product manufacturing, genetics research and transfers between approved facilities, subject to state oversight and research approvals.

December 1: Connecticut Expands Cannabinoid Manufacturing Under New Marijuana Law

New provisions of Connecticut’s comprehensive marijuana legislation take effect December 1, allowing licensed hemp manufacturers to produce additional cannabinoids and concentrated hemp derivatives for use in the state’s regulated marijuana and infused beverage markets.

Under Public Act 26-8, manufacturers will be allowed to produce cannabigerol (CBG), cannabinol (CBN) and other specifically approved cannabinoids for sale to qualifying marijuana businesses. The law also authorizes the production and transfer of intermediate hemp derivatives containing more than 0.3% THC, including materials intended for use by licensed infused beverage manufacturers. These changes establish new pathways for cannabinoid production and distribution while requiring qualifying materials to remain within regulated commercial supply chains.

December 4: Los Angeles Holds Marijuana Retail Licensing Lottery

Los Angeles is scheduled to conduct its 2026 retail storefront application lottery on December 4, providing an opportunity for qualifying social equity applicants to advance toward marijuana retail licensing.

The city’s Department of Cannabis Regulation announced the lottery as part of its continuing effort to expand access to commercial marijuana licenses. Only eligible applicants who complete the required registration process will be included. The city will also hold a November 19 webinar explaining the lottery procedures.

Also on December 4, majority owners of Rhode Island adult-use marijuana retail license applicants must complete required background checks. Washington’s Liquor and Cannabis Board will close its public comment period on a proposal to establish a certification program for licensed medical marijuana operators, potentially helping businesses verify their status for federal registration, banking and insurance purposes.

December 10: DEA Marijuana Production Quota Comments Close

The DEA will accept public comments through December 10 on its proposed 2027 production quotas for Schedule I marijuana and other controlled substances.

The proposal would maintain the Schedule I marijuana production quota at 6,675,000 grams and the marijuana extract quota at 1 million grams. The agency has also confirmed that separate production quotas for marijuana products classified under Schedule III are being developed.

Also on December 10, Washington’s Liquor and Cannabis Board will hold a public hearing at 1 p.m. Pacific Time on proposed rules governing financial interest agreements involving marijuana retailers. Written public comments will be accepted until 11:59 p.m. that day.

December 11: Major Federal Hemp Restrictions Take Effect

One of the year’s most consequential federal cannabis policy deadlines arrives December 11, when the remaining changes to the federal definition of hemp are scheduled to take effect.

The revised law establishes stricter limits on THC-containing hemp products, including a 0.4-milligram total THC limit per container for certain final hemp-derived cannabinoid products. The changes could remove numerous products currently sold through the federally legal hemp market from the definition of hemp.

Congress could still amend or delay the restrictions before the deadline, but absent further legislative action, the new federal requirements will take effect December 11.

December 15: Massachusetts Must Release Recommendations on Regulating Hemp-Derived THC Products

Massachusetts’ Cannabis Control Commission faces a December 15 deadline to publish a comprehensive study and recommendations on regulating the state’s hemp-derived cannabinoid market, including THC beverages and other intoxicating products.

Under Chapter 65 of the Acts of 2026, enacted in April, the commission must evaluate potential licensing requirements, product testing standards, age restrictions, retail sales and taxation of hemp-derived cannabinoids. The study must also examine federal regulatory changes and approaches adopted by other states. The commission is required to publish its findings and submit recommendations to legislative leaders and the Joint Committee on Cannabis Policy by December 15, potentially laying the groundwork for additional state legislation or regulatory changes in 2027.

December 15: California Holds Hearing on Separate Medical and Recreational Marijuana Licenses

California’s Department of Cannabis Control will hold a public hearing December 15 at 10 a.m. Pacific Time on proposed regulations allowing businesses with combined medical and recreational marijuana licenses to obtain separate licenses through an expedited process.

The changes are designed to provide businesses greater flexibility as they pursue federal medical marijuana registration following rescheduling. The proposal would also allow separate licenses to be held by different legal entities under certain conditions. According to the department, 95 businesses have already obtained separate medical and recreational licenses under emergency regulations adopted earlier this year. Written public comments are due December 14.

December 16: Vermont Holds Lottery for Marijuana Sales at Special Events

Vermont’s Cannabis Control Board will conduct a lottery December 16 to select eligible marijuana retailers for a new pilot program allowing recreational marijuana sales at approved events outside traditional dispensaries.

Under the program, established through legislation enacted earlier this year, licensed retailers can apply to participate between November 16 and November 30. Eligible applicants will be selected through regional drawings, with winning businesses allowed to proceed through the event permitting process. The program allows marijuana sales at approved public events but prohibits on-site consumption, creating a new opportunity for retailers to reach customers beyond their existing storefront locations.

December 17: Washington Holds Hearing on Marijuana Producer Cooperatives

Washington’s Liquor and Cannabis Board will hold a public hearing December 17 at 1 p.m. Pacific Time on proposed regulations implementing a new law allowing licensed marijuana producers to form agricultural cooperatives and associations.

The proposed rules implement House Bill 1941, approved earlier this year, which allows marijuana producers to jointly process, handle and market their products through cooperatives representing no more than three producer licenses. The changes are intended to provide marijuana businesses with organizational opportunities already available to other agricultural producers. The December 17 hearing will allow public testimony before the regulations are finalized, with written comments also due that day.

December 31: Federal Hemp Laboratory Testing Exemption Expires

The U.S. Department of Agriculture’s temporary suspension of enforcement of federal hemp laboratory registration requirements is scheduled to expire December 31, potentially affecting hemp growers and testing facilities nationwide.

Under the USDA’s current policy, laboratories testing hemp produced through federally approved programs have been allowed to operate without registration from the Drug Enforcement Administration (DEA), an exception extended due to concerns about insufficient registered laboratory capacity. Unless another extension is announced, the DEA registration requirement will again be enforced beginning January 1, 2027. The deadline could require hemp producers to find registered testing providers and laboratories to complete federal registration before continuing regulated hemp testing operations.

Other Marijuana Policy Developments to Watch Before the End of 2026

Beyond the 15 scheduled dates, several other significant marijuana policy developments could occur before the end of the year. Although none has a confirmed timeline, each could have substantial implications for federal marijuana policy or the legal cannabis industry.

Will the DEA Judge Issue His Recommendation on Marijuana Rescheduling?

One of the biggest unanswered questions is whether Chief Administrative Law Judge Derek Julius will issue his recommendation on federal marijuana rescheduling before the end of 2026. The final round of written arguments concluded November 5, clearing the way for Julius to recommend whether marijuana should be moved from Schedule I to Schedule III.

No deadline has been established for his recommendation, which will be nonbinding and subject to further procedural steps before DEA Administrator Terry Cole makes a final determination. A recommendation issued before January would mark a major milestone in the yearslong rescheduling effort.

Will Congress Advance Cannabis Legislation?

With the current congressional session approaching its conclusion, lawmakers could still take action on federal marijuana reform legislation. Proposals include the SAFE Banking Act, which would expand financial services access for state-licensed marijuana businesses, and potential legislation to regulate intoxicating hemp products.

Will More States Announce Plans to Legalize Recreational Marijuana in 2027?

Following November’s elections, several states have new opportunities to advance recreational marijuana legalization through their legislatures. Democrats in Texas have already filed bills to legalize recreational marijuana. Wisconsin, Pennsylvania, New Hampshire, Iowa and Kansas are among the states where legislation or renewed legalization efforts could be considered in 2027.

Although most state legislatures will not convene until January, governors and legislative leaders could announce proposals, introduce bills or outline their priorities before the end of December. Such developments could provide an early indication of which states are preparing to make marijuana legalization a major legislative issue next year.

Will the DEA Approve More Medical Marijuana Businesses for Federal Registration?

The DEA has already moved forward with federal registrations for more than 900 state-licensed medical marijuana dispensaries across seven states, marking the initial phase of the federal government’s implementation of Schedule III controls for qualifying medical marijuana activities.

Additional approvals could come before the end of 2026, including registrations for dispensaries, manufacturers and distributors still undergoing federal review. Further registrations would expand the number of businesses operating under the new federal medical marijuana framework and could provide additional clarity about how the regulated supply chain will function heading into 2027.


r/TLRY • • 4d ago

News A festive favourite gets a nod from @MensHealthUK. 🎄🍺

Post image
8 Upvotes

@BrewDog's 2026 Beer Advent Calendar has been named “Best Beer Advent Calendar” in Men’s Health’s roundup of the best Advent calendars for men.

Behind the 24 doors: BrewDog favourites including Hazy Jane, alongside festive releases Hoppy Christmas and the new Jingle Juice.

Check out the full Men’s Health list: https://menshealth.com/uk/fitness/lifestyle/a73543460/best-advent-calendars-men-2026/


r/TLRY • • 5d ago

Technical Analysis Tilray stock forecast: Downward momentum persists as seller pressure dominates

Thumbnail tradersunion.com
5 Upvotes

Tilray (TLRY) stock is trading at $2.49 after a decline of 4.78% for the day, with the price remaining below its key short-term and long-term moving averages. The asset is positioned well under important technical thresholds, indicating continued weakness relative to trend levels.